Interestingly, activation of DR5 in cardiomyocytes resulted in protective signaling suggesting that therapeutically targeting DR5 might be beneficial for the treatment of heart failure, which is in accordance with many of the clinical studies that suggest a beneficial role of TRAIL/DR5 (7–9). Here, TNFRSF10B is linked to heart failure.